-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $24

Benzinga·06/06/2025 15:06:12
Listen to the news
Goldman Sachs analyst Matt Dellatorre initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $24.